Answers are grounded in this paper and cite their sources.
The article considers a clinical case that clearly demonstrates the positive effect of a combination of targeted therapy, including CDK4/6i (ribociclib), and an aromatase inhibitor in the first line of therapy in a premenopausal patient with hormonal receptor-positive HER2-negative (HR+/HER2-) metastatic breast cancer.
No takes yet. Share an insight, caveat, or question.
Shatokhina et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: